✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #30
Stoke Therapeutics to Present STK-002 Data at AAO 2026
Original: Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics said its investigational therapy STK-002, being developed for autosomal dominant optic atrophy, a rare genetic eye disease that causes progressive vision loss, will be featured in presentations at the American Academy of Ophthalmology 2026 Annual Meeting. The company made the announcement ahead of the meeting; details of the study results have not yet been reported.
Why now: Investors and the rare disease community follow conference presentations for early evidence of whether the experimental therapy works.
Stoke TherapeuticsSTK-002American Academy of Ophthalmology
Rank over time, top of the chart is #1. 2 snapshots from 1 d ago to 1 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1359264